IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
De scrip tion: De vel oper, man u fac turer, for mu la -
tor, packager/as sem bler, im porter, ex porter, dis -
trib u tor, pro moter, sales/detailer. Man u fac tures
for other com pa nies. Prod uct ranges in clude:
phar ma ceu ti cal prod ucts (branded, unbranded,
pre scrip tion, non-pre scrip tion), hos pi tal
pharmaceuticals, fine chem i cals, raw ma te ri als,
bio tech nol ogy prod ucts, oph thal mic prod ucts,
vet er i nary pharmaceuticals. Es tab lished 1997.
1,438 phar ma ceu ti cal em ploy ees in 2007.
Divisions include: Novartis Consumer Health.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 595 (2007)
Con tacts (Pharm): Chair man: Al ex an der
Triebnigg; Com mer cial Op er a tions: Marcelo
Morkoski; Man u fac ture: Valdemar Grober; Mar -
ket Re search: Camila Finzi; Re search & De vel op -
ment: An dre Feher; Gen eral Con tact: Celso
Massatoshi Sato
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 540-560 mil lion
Prod ucts (% of Sales by Lead ing 5): 35-40%
Ther a peu tic Classes (% of Sales by Lead ing
5): 65-70%
Dose Forms (% of Sales by Lead ing 5):
95-100%
Prin ci pal Prod ucts:
DIOVAN HCT (an gio ten sin-II an tag o nist com bi na -
tion)
DIOVAN (an gio ten sin-II an tag o nist plain)
PREXIGE (antirheumatic non-steroidal)
FORASEQ (B2-stim u lant/corticoid com bi na tion)
EXELON (anti-Alz hei mer prod uct)
Ther a peu tic Range:
renin-an gio ten sin sys tem agents 27%
anti rheu ma tics sys temic 16%
antiasthma and COPD prod ucts 9%
antiepileptics 8%
psychoanaleptics 7%
Lead ing Dose Forms:
coated tab lets 50%
tab lets 24%
cap sules 17%
liq uids 4%
med i cal dress ings 2%
SANDOZ
Full Name: Sandoz do Brasil In du stria
Farmaceutica Ltda.
Street Ad dress: Av. Itaborai, 1425, Bosque da
Saude, 04135-001 Sao Paulo SP
Tel: +55 11-5591 7600
Fax: +55 11-5591 7600
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 210-220 mil lion
Prod ucts (% of Sales by Lead ing 5): 15-20%
Ther a peu tic Classes (% of Sales by Lead ing
5): 45-50%
Dose Forms (% of Sales by Lead ing 5):
95-100%
Prin ci pal Prod ucts:
SINVASTACOR (cho les terol/triglyceride reg u lat -
ing prep a ra tion)
SINVASTATINA MG (cho les terol/triglyceride reg -
u lat ing prep a ra tion)
CLOPIDOGREL MG (platelet ag gre ga tion in hib i tor)
AMIDALIN (throat prep a ra tion)
CLO SIBUTRAMINA MG (antiobesity prep a ra tion
non-di etetic)
Ther a peu tic Range:
antibacterials sys temic 15%
renin-an gio ten sin sys tem agents 11%
lipid-reg u lat ing/antiatheroma prep a ra tions
10%
ant ac ids/antiflatulents/antiulcerants 7%
psychoanaleptics 6%
Lead ing Dose Forms:
tab lets 42%
coated tab lets 38%
cap sules 13%
spe cial solid forms 3%
liq uids 3%
BULGARIA
HEXAL
Street Ad dress: Et. 1, App. 3, 19, “Tzar Assen”
Street, 1000 So fia
De scrip tion: Rep re sen ta tive of fice. Es tab lished
2000.
Con tacts (Pharm): Chair man: Dr Ray Masch
NOVARTIS
Full Name: Novartis Pharma Ser vices Inc
Street Ad dress: Busi ness Park So fia, Build ing
8C, 6th floor, 1766 So fia
Tel: +359 2 489 9828
Fax: +359 2 489 9829
Home Page: www.mea.novartis.com
De scrip tion: Rep re sen ta tive of fice. Prod uct
ranges in clude: phar ma ceu ti cal prod ucts. 45
phar ma ceu ti cal em ploy ees in 2008. Di vi sions in -
clude: Novartis Consumer Health.
© 2009 IMS Health In cor po rated or its af fil i ates Page 155